What is Entopsis?
Entopsis operates at the intersection of advanced chemistry and diagnostic technology. Its core innovation, the NuTec platform, utilizes a unique chemical hashing methodology to identify biomolecules with high precision. Unlike traditional diagnostic frameworks that require disparate testing protocols for individual conditions, the NuTec system is engineered to detect multiple analytes from a single sample. This capability is designed to streamline clinical workflows, reduce diagnostic costs, and improve patient outcomes through rapid, actionable data. As an ISO-certified entity, Entopsis maintains rigorous manufacturing standards, ensuring that its diagnostic devices meet the stringent requirements of both medical and industrial applications. The company's focus on versatility—spanning from food safety compliance to complex medical diagnostics—positions it as a disruptive force in the molecular identification market.
How much funding has Entopsis raised?
Entopsis has raised a total of $800K across 1 funding round:
Angel/Seed
$800K
Angel/Seed (2015): $800K with participation from Krillion Ventures
Key Investors in Entopsis
Krillion Ventures
Krillion Ventures is a Miami-based venture capital fund that invests in early stage technology companies focused on healthcare, financial services, and real estate.
What's next for Entopsis?
Looking ahead, the strategic roadmap for Entopsis involves the aggressive expansion of its NuTec platform's diagnostic library and the optimization of its manufacturing processes. The recent capital influx will likely be directed toward clinical validation studies and the scaling of production capacity to meet anticipated demand in the healthcare sector. Furthermore, the company is expected to explore strategic partnerships that could facilitate the integration of its technology into existing clinical infrastructures. By maintaining its commitment to cost-effective, high-throughput molecular analysis, Entopsis is poised to redefine the standards of rapid diagnostics, potentially shifting the industry paradigm toward more accessible and comprehensive health monitoring systems.
See full Entopsis company page
